Autoimmune Treatment Updates: Thyroid Eye Disease Approval and Early Kv1.3 Data

A report says Genentech’s Enspryng was FDA-approved for thyroid eye disease, but the available account lacks trial, benefit-size, and safety details that are needed to assess the claim and its clinical implications. Zealand Pharma’s ZP9830 phase I multiple-dose study in 32 healthy participants reported no serious or severe adverse events or dose-limiting findings over four weeks; patient benefit and longer-term safety remain unknown.